In May 2021, amivantamab received marketing approval from the U.S. FDA, primarily for the treatment of patients with EGFR exon 20 insertion mutation NSCLC who have progressed during or after platinum-based chemotherapy.
On October 26, 2023, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Johnson & Johnson's EGFR/c-Met bispecific antibody therapy, amivantamab, had submitted a marketing application and been formally accepted.
Janssen Pharmaceuticals is currently applying to the U.S. Food and Drug Administration (FDA) for a new indication for its cutting-edge drug amivantamab, to treat lung cancer patients with EGFR 19/21 mutations who have progressed with resistance to osimertinib.
Clinical trial data show that novel dual or triple regimens of ervaltumab improved progression-free survival and significantly reduced the risk of disease progression and death in patients.
